Full-Time

Senior Product Manager

Cloud Visualization Software

Posted on 12/7/2024

10x Genomics

10x Genomics

1,001-5,000 employees

Biotechnology tools for genomic research

Biotechnology
Healthcare

Compensation Overview

$149.7k - $224.9kAnnually

+ Equity Grants + Annual Bonus

Mid, Senior

Pleasanton, CA, USA

This position is based at the company headquarters in Pleasanton, California.

Category
Product Management
Product
Required Skills
Product Management
Product Design

You match the following 10x Genomics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree (or equivalent).
  • 3 years of experience in product management, software management, or equivalent experience in a related field.
Responsibilities
  • Conduct customer and user research, assess the business and competitive landscape, and analyze product data to inform prioritization and design decisions.
  • Collaborate with cross-functional teams (software engineering, product design, QA, and computational biology) to translate customer requirements into actionable features.
  • Define and prioritize product roadmaps, balancing customer needs with technical feasibility and business goals.
  • Oversee software development cycles, ensuring timely delivery of impactful features.
  • Act as a bridge between technical and non-technical stakeholders, ensuring alignment and clarity in product direction.
  • Drive the successful release of software products, from ideation to post-launch refinement.
Desired Qualifications
  • Exceptional problem-solving skills, including the ability to abstract and identify patterns from complex scenarios.
  • Customer empathy, with a keen ability to synthesize user feedback into actionable insights.
  • Strong understanding of user experience design principles.
  • Exceptional written and verbal communication skills, with an ability to translate technical concepts for diverse audiences.
  • Robust project management skills with a proven ability to handle competing priorities and meet deadlines.
  • Experience managing cloud-based software products.
  • Familiarity with cloud infrastructure and its implications for development and deployment.
  • Proficiency in leveraging product analytics and analysis tools (e.g., SQL, Python, Plotly, Mixpanel) to inform and guide decisions.
  • Experience in life sciences, bioinformatics, or genomics.
  • Familiarity with compliance frameworks such as GDPR and GxP.

10x Genomics provides tools and technologies for genomic research, focusing on single-cell analysis, spatial gene expression, and immune profiling. Their products enable researchers to analyze genetic information in detail, which is crucial for understanding complex biological systems and advancing personalized medicine. The company differentiates itself by offering high-quality laboratory equipment, consumables, and software solutions, along with ongoing support for clients in academic and clinical settings. The goal of 10x Genomics is to empower scientists to explore the human genome and contribute to the development of new treatments.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$214.9M

Headquarters

Pleasanton, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for personalized medicine boosts need for 10x Genomics' high-resolution data tools.
  • AI integration in genomics enhances data analysis, benefiting 10x Genomics' software offerings.
  • Expansion of CRISPR applications increases demand for precise genomic analysis tools.

What critics are saying

  • Increased competition in single-cell analysis could impact 10x Genomics' market share.
  • Patent litigation with Bruker Corporation poses legal and financial risks.
  • Reliance on limited suppliers risks supply chain disruptions affecting production timelines.

What makes 10x Genomics unique

  • 10x Genomics offers unique single-cell and spatial analysis tools for detailed genomic research.
  • Their On-Chip Multiplex solution reduces handling time, enhancing laboratory efficiency.
  • The company provides cost-effective genomic solutions, democratizing access to single-cell analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health benefits

Generous time off

Parental leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Jan 12th, 2025
10X Genomics Announces Preliminary Select Fourth Quarter And Full Year 2024 Results

FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentiallyPLEASANTON, Calif., Jan. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024.Preliminary, Unaudited Select Fourth Quarter 2024 Financial ResultsRevenue of approximately $165.0 million for the three months ended December 31, 2024 , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period.for the three months ended , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period. Instruments revenue of approximately $24.4 million , representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately $10.9 million of Chromium instruments revenue and $13.4 million of Spatial instruments revenue., representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately of Chromium instruments revenue and of Spatial instruments revenue

Securities.io
Jan 7th, 2025
Can Ai Predict One’S Metabolomic Age And Tailor Health Plans Accordingly?

Artificial intelligence continues to push the boundaries of science and health exploration. From mapping proteins to neurological networks, these systems continue to make game-changing impacts on the sector. This month, a group of advantageous researchers from the Institute of Psychiatry, Psychology & Neuroscience took AI integration further. They released a study in which AI algorithms were used to predict the metabolic age of patients. Here's what you need to know.Chronological Clock vs Biological ClockTo grasp the importance of this development, it's vital to understand the differences between your chronological and biological age. These two methods of determining the age of your body are used in different ways by healthcare professionals

PR Newswire
Jan 2nd, 2025
10X Genomics To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health

Stock Titan
Jan 2nd, 2025
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ - 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.

Pulse Press
Dec 25th, 2024
Bruker 'respectfully disagrees' with District Court, to seek stay of injunction

"Yesterday, the Court issued its ruling on the post-trial motions that followed the November 2023 jury verdict in the patent infringement case between NanoString and 10x Genomics.

PR Newswire
Dec 23rd, 2024
U.S. District Court Awards 10X Genomics Permanent Injunction In Patent Infringement Lawsuit Against Bruker Corporation'S Geomx Products

PLEASANTON, Calif., Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023.The injunction, which the Court said it will enter in January 2025, is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023

GeneSmart
Nov 25th, 2024
GEM-X Universal OCM: Optimizing Cost and Improving Efficiency in Single-Cell Research

To overcome this challenge, 10X Genomics introduced the On-Chip Multiplex (OCM) solution, enabling multiplexing directly on the chip and eliminating the need for complex sample preparation, thus reducing handling time.

PR Newswire
Oct 15th, 2024
10X Genomics Delivers 'Single Cell For A Single Cent' With New Chromium Launches

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications.These launches are part of the company's strategy to drive widespread adoption of single cell analysis by lowering customer costs in multiple directions: per cell, per sample, per experiment and per project. With these advances, 10x Genomics is addressing the growing demand for high-throughput single cell applications and providing cost-effective offerings to help new researchers getting started in single cell and existing labs looking to scale up their research."These launches are an integral part of our ongoing push to democratize single cell analysis and make it more accessible and more affordable for more researchers than ever before," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "They add to a growing list of new single cell products, protocols and capabilities that make 2024 the most exciting year of Chromium innovation in the platform's history

BioSpace
Oct 12th, 2024
10X Genomics Announces Preliminary Select Third Quarter 2024 Results

PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.Preliminary Select Third Quarter 2024 ResultsRevenue of approximately $151.7 million for the third quarter ended September 30, 2024 , representing an approximate 1% decrease from the corresponding prior year period.for the third quarter ended , representing an approximate 1% decrease from the corresponding prior year period. Preliminary revenue by source for the third quarter is expected to be as follows: Instruments revenue of approximately $19.1 million , representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue. Consumables revenue of approximately $126.2 million , representing 10% growth over the corresponding prior year period

Investing.com
Oct 2nd, 2024
10X Genomics hold rating reiterated by TD Cowen

The decision came after 10X Genomics revealed plans at an industry event to introduce new Single Cell (SC) products in the fourth quarter.

INACTIVE